Isoniazid Preventive Therapy and Pregnancy Outcomes in Women Living With Human Immunodeficiency Virus in the Tshepiso Cohort

Nicole Salazar-Austin,1,6 Silvia Cohn,1 Sanjay Lala,2,3 Ziyaad Waja,3 Kelly E. Dooley,1 Christopher J. Hoffmann,1 Richard E. Chaisson,1 and Neil Martinson1,3; and the TSHEPISO Study Team

1Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, 2Department of Paediatrics, Chris Hani Baragwanath Hospital and University of the Witwatersrand, Soweto, South Africa, and 3Perinatal HIV Research Unit, University of the Witwatersrand, Soweto, South Africa

Background. Both pregnancy and human immunodeficiency virus (HIV) increase the risk of tuberculosis disease, which results in poor maternal, pregnancy, and infant outcomes. Isoniazid preventive therapy (IPT) reduces mortality among individuals living with HIV in high-burden settings but has recently been associated with adverse pregnancy outcomes when initiated during pregnancy.

Methods. In this secondary analysis, we used multivariable logistic regression to evaluate the association between IPT exposure and adverse pregnancy outcomes (fetal demise, prematurity, low birth weight, congenital anomaly) in pregnant women living with HIV enrolled as controls in the Tshepiso study, a prospective observational cohort of pregnant women living with HIV with and without tuberculosis disease in Soweto, South Africa, from 2011–2014.

Results. There were 151 women enrolled with known pregnancy outcomes; 69 (46%) reported IPT initiation during pregnancy. Of the 69 IPT-exposed women, 11 (16%) had an adverse pregnancy outcome compared with 23 (28%) IPT-unexposed women. The adjusted odds of having an adverse pregnancy outcome was 2.5 (95% confidence interval, 1.0–6.5; P = .048) times higher in IPT-unexposed women compared with IPT-exposed women after controlling for maternal age, CD4 count, viral load, antiretroviral regimen, body mass index, and anemia.

Conclusions. IPT exposure during pregnancy was not negatively associated with pregnancy outcomes after controlling for demographic, clinical, and HIV-related factors. These results provide some reassurance that IPT can be safely used in the second or third trimester of pregnancy. Additional research is needed to evaluate the safety of IPT and new short-course tuberculosis preventive therapies during pregnancy.

Keywords. tuberculosis; pregnancy; isoniazid preventive therapy (IPT); pregnancy outcomes.

Tuberculosis (TB) remains the leading infectious cause of death worldwide, killing 476,000 women in 2017 [1]. Both pregnancy and human immunodeficiency virus (HIV) increase a woman’s risk of TB disease [2, 3]. In sub-Saharan Africa, the World Health Organization (WHO) estimates a 10-fold higher prevalence of TB disease among pregnant women living with HIV compared with pregnant women not living with HIV [4]. Maternal TB disease has devastating consequences for both mothers and infants including increased maternal and infant mortality, adverse pregnancy outcomes including prematurity and low birth weight, infant TB, and perinatal HIV transmission [5–15].

Isoniazid preventive therapy (IPT) in people living with HIV (PLHIV) in high TB burden settings provides a durable benefit on preventing both TB and mortality, independent of and strengthened by coadministration of combination antiretroviral therapy (cART) [16, 17]. However, the safety of IPT in pregnancy is not well established, and concerns remain for increased risk of maternal hepatotoxicity [18, 19]. Nevertheless, IPT has been recommended for pregnant women living with HIV in high-burden settings since 1993 [20]. TB APPRISE, a phase 4 randomized, controlled trial evaluating the safety and timing of IPT initiation among pregnant women living with HIV in high TB burden settings, reported no difference in maternal hepatotoxicity but, unexpectedly, found a higher risk of adverse pregnancy outcomes (fetal demise, prematurity, low birth weight, and congenital anomaly) among mothers who received IPT during pregnancy than in the postpartum period [21]. Two additional observational substudies of TB preventive therapy trials assessing the use of daily and weekly isoniazid during pregnancy or at conception found no association between isoniazid use and adverse pregnancy outcomes [22, 23].
Defining the association between isoniazid and adverse pregnancy outcomes is crucial given the large number of pregnant women living with HIV in low-resource settings at extreme risk of TB disease and its maternal and infant complications and the well-established survival benefit of IPT in this setting. Given the unexpected association between IPT and adverse pregnancy outcomes found in TB APPRISE and the conflicting observational data, we aimed to add to the body of knowledge on the safety of IPT in pregnancy. Here, we examined the association between IPT and pregnancy outcomes in a secondary analysis of a well-characterized prospective cohort of pregnant women living with HIV in Soweto, South Africa, from 2011–2014.

METHODS

Study Design

Tshepiso was a prospective matched cohort study of pregnant women living with HIV with and without TB disease. Pregnant women were recruited from 10 prenatal clinics in Soweto, South Africa, from January 2011 through January 2014 [5]. The study enrolled pregnant women living with HIV aged ≥18 years and at least >13 weeks’ gestation. For each woman with TB disease, 2 pregnant women living with HIV without TB disease were enrolled as controls and matched by age (±5 years), gestational age (±2 weeks), date of their first prenatal visit (±8 weeks), and, to avoid bias by indication for place of delivery, their planned delivery clinic. All women had a sputum sample taken for liquid mycobacterial culture (BACTEC MGIT 960 System) to confirm TB disease in women with TB and to confirm absence of pulmonary TB in controls. This study was noninterventional; all women and children received care at public sector clinics in Soweto according to South African ART and TB guidelines. The Tshepiso study doctor offered IPT to all study participants without TB disease who had not been initiated on IPT at public sector clinics. Follow-up and isoniazid refills were provided to all participants at public sector clinics. Here, we report the maternal, pregnancy, and infant outcomes among pregnant women living with HIV without TB disease who did or did not report isoniazid use for TB prevention during pregnancy.

Prevention and Treatment Guidelines for HIV and TB

For the first 2 years of the study, South African prevention of mother-to-child transmission (PMTCT) guidelines recommended WHO's option A, that is, efavirenz (EFV)-based antiretroviral therapy when CD4 count is ≤350 and zidovudine (AZT) monotherapy, with single-dose nevirapine at the initiation of labor, intrapartum AZT, and 1 postpartum dose of tenofovir and emtricitabine when CD4 count is >350 [24]. In March 2013, South Africa began to recommend option B with EFV-based antiretroviral therapy either as prophylaxis for the duration of pregnancy and breastfeeding or lifelong cART for those with CD4 count <350 or a stage 3 or 4 illness [25].

For the duration of the study, IPT was recommended for all eligible individuals living with HIV prior to or after initiating cART for a 6-month duration [26]. IPT eligibility was assessed by clinical history only. PLHIV not eligible for IPT included those with symptoms of TB disease, active liver disease, and/or active alcohol abuse. Notably, pregnancy was not a contraindication.

Data Collection

Mother–infant pairs were enrolled during the second or third trimester and followed at 1 week, 6 weeks, 6 months, and 12 months postdelivery for maternal, pregnancy, and infant outcomes including TB incidence and mortality. All outcomes were self-reported and confirmed using clinic and hospital records and the infant’s road-to-health card. IPT exposure was assessed by self-report at each visit and confirmed using medical records, when available. Laboratory testing was performed by Clinical Laboratory Services, an accredited commercial research laboratory.

Exposures and Outcomes

For the purpose of this study, isoniazid exposure was defined as self-reported use of isoniazid for TB prevention of any duration while pregnant. Measured pregnancy outcomes included spontaneous abortion (<28 weeks), stillbirth (≥28 weeks), prematurity (<37 weeks), birth weight, size for gestational age, and congenital anomaly. Long-term outcomes included incident maternal and infant TB disease and infant and maternal mortality. Gestational age was determined by the date of the last menstrual period. Maternal mortality was defined as maternal death within 42 days of delivery and infant mortality as infant death within the first year of life. Low birth weight and small size for gestational age were defined as birth weight <2.5 kg and <10th percentile, respectively [27]. Measured confounding variables included CD4 count at enrollment (cells/µL), viral load at enrollment or nearer to delivery (copies/mL), PMTCT regimen at delivery, hemoglobin and body mass index (BMI) at enrollment, and sociodemographic factors including maternal age at enrollment, race, education, and income.

For this analysis, we defined 3 composite outcomes. First, adverse pregnancy outcome included fetal demise (spontaneous abortion <28 weeks and stillbirth >28 weeks), low birth weight (<2.5 kg), prematurity (<37 weeks), and/or major congenital anomaly (according to the Centers of Disease Control and Prevention Metropolitan Atlanta Congenital Defects Program [MACDP] criteria [28]), as defined in other PMTCT and TB studies [21, 29]. Second, severe adverse pregnancy outcome included fetal demise, very low birth weight (<1.5 kg), very preterm delivery (<33 weeks), and/or major congenital anomaly (MACDP criteria [28]). Third, maternal/infant TB or death included maternal mortality, fetal demise, infant mortality, and/or maternal or infant TB within 1 year of delivery, as defined in other maternal TB studies [21].
Statistical Analyses
Demographic and clinical characteristics of pregnant women were described using proportions for categorical variables and means with standard deviations (SDs) and medians with interquartile ranges (IQRs) for normally and nonnormally distributed continuous variables, respectively. We used Pearson χ² tests or Fisher exact tests to compare categorical variables and Student t tests or Mann-Whitney U tests to compare continuous variables. Multivariable logistic regression models were used to describe the association between IPT exposure (exposure of interest) and adverse pregnancy outcomes (composite outcome). We adjusted for potential confounders identified a priori including maternal age, CD4 count, viral load, antiretroviral regimen, BMI, and hemoglobin. Collinearity was assessed using variance inflation factors.

Maternal age, CD4 count, viral load, hemoglobin, and BMI were assessed as both continuous and categorical variables. CD4 count and viral load categories were informed by clinically relevant thresholds used at the time the study was conducted [30–33]. Categories for maternal age, BMI, and anemia (hemoglobin) were based on published categories [30, 34–37], notably prior established BMI categories used BMI measured in the first trimester.

We performed a complete case analysis. Loss to follow-up was considered random and not due to isoniazid exposure. Data were analyzed using SAS statistical software (version 9.4) [38].

Ethical Approval
The University of Witwatersrand Human Research Ethics Committee and the Johns Hopkins Institutional Review Board approved this study. Written informed consent for all participants was obtained prior to enrollment.

RESULTS
The study enrolled 155 women without TB disease (Figure 1). Of these, 71 (46%) reported use of IPT (IPT exposed) during pregnancy and 84 (54%) did not (IPT unexposed). Among IPT-exposed women, 1 woman relocated prior to delivery and 1 woman was lost to follow-up. Among IPT-unexposed women, 2 withdrew consent. Pregnancy outcomes were available for 69 (97%) and 82 (98%) women with and without IPT exposure, respectively. Long-term outcomes including TB disease and mortality, assessed at 1 year postdelivery, were available for 65 (92%) and 64 (76%) of IPT-exposed and IPT-unexposed women. Among IPT-exposed mothers, reasons for not completing follow-up were relocation (n = 1), loss to follow-up (n = 1), and other reasons (n = 2). Among IPT-unexposed mothers, reasons were relocation (n = 6), withdrawal of consent (n = 1), loss to follow-up (n = 3), death (n = 2), and other reasons (n = 6).

Among the 151 women who delivered, there was 1 set of twins and 2 stillbirths, resulting in 150 live births including 68 live births with IPT exposure in utero and 82 live births without IPT exposure in utero. A higher proportion of IPT-exposed infants (n = 61, 90%) were followed through infancy than...
IPT-unexposed infants (n = 66, 80%). Reasons for not completing a year of follow-up were similar across the 2 groups and included withdrawal of consent (n = 0 vs 1), relocation (n = 2 vs 6), loss to follow-up (n = 3 vs 5), death (n = 1 vs 0), and other reasons (n = 1 vs 4).

Maternal Characteristics at Enrollment

Maternal characteristics at enrollment were similar in IPT-exposed and IPT-unexposed participants (Table 1). Both groups had a mean age of 29 years (SD, 4.6 and 3.8, respectively). Mean gestational age at enrollment was 29 weeks (SD, 5.8) in the IPT-exposed group and 31 weeks (SD, 5.3) in the IPT-unexposed group (P = .01). The IPT-exposed and IPT-unexposed groups had similar parity, number of prior miscarriages, median hemoglobin, median BMI, race, education, and employment.

Baseline CD4 counts at enrollment were similar between the groups, 373 cells/µL (IQR, 275 to 477) among IPT-exposed participants and 364 cells/µL (IQR, 252 to 464) among IPT-unexposed participants. At delivery, similar proportions of participants received either AZT monotherapy with single-dose nevirapine at birth or cART. One participant refused both cART and AZT monotherapy for PMTCT but accepted IPT.

Table 1. Characteristics of Maternal Pregnancy, Human Immunodeficiency Virus Disease, and Prior Tuberculosis Disease by Isoniazid Exposure

| Characteristic                                      | IPT          | No IPT         | P Value |
|-----------------------------------------------------|--------------|----------------|---------|
| N = 151 Total                                       | n = 69       | n = 82         |         |
| Sociodemographic characteristics at study enrollment|              |                |         |
| Median maternal age at study enrollment (SD), y     | 29 (4.8)     | 29 (3.8)       | .83     |
| Number of participants contributing to this calculation| n = 69       | n = 82         |         |
| Median gestational age at study enrollment (SD), wk | 29 (5.8)     | 31 (5.3)       | .01     |
| Number of previous deliveries (%)                   | n = 69       | n = 82         |         |
| 0                                                   | 2 (3)        | 7 (9)          | .31     |
| 1                                                   | 32 (48)      | 32 (39)        |         |
| 2                                                   | 23 (33)      | 27 (33)        |         |
| ≥3                                                  | 4 (6)        | 9 (11)         |         |
| Unknown                                             | 8 (12)       | 7 (9)          |         |
| Prior miscarriage, N (%)                            |              |                | .38     |
| 0                                                   | 53 (77)      | 61 (74)        |         |
| ≥1                                                  | 8 (12)       | 14 (17)        |         |
| Unknown                                             | 8 (12)       | 7 (9)          |         |
| Race, N (%)                                         |              |                | 1.00    |
| Black African                                       | 68 (99)      | 82 (100)       |         |
| Other                                               | 1 (1)        | 0 (0)          |         |
| Education, N (%)                                    |              |                | .56     |
| ≤ 8th grade                                         | 6 (9)        | 8 (10)         |         |
| 9th–12th grade                                      | 36 (52)      | 36 (44)        |         |
| Completed 12th grade                                | 26 (38)      | 34 (41)        |         |
| Started or completed a tertiary degree              | 1 (1)        | 4 (5)          |         |
| Employment (prior 12 months), N (%)                  |              |                | .72     |
| Currently employed                                  | 15 (22)      | 20 (24)        |         |
| Previously employed in the past year                | 19 (27)      | 18 (22)        |         |
| Unemployed in the last year                         | 35 (51)      | 44 (54)        |         |
| Median hemoglobin at study enrollment (SD), g/dL    | 11.2 (1.3)   | 11.3 (1.3)     | .70     |
| Median body mass index at study enrollment (SD), kg/m²| 278 (4.4)    | 28.4 (5.2)     | .49     |
| Characteristics of HIV infection at screening for study enrollment|       |                |         |
| Median CD4 T-cell count at study enrollment (IQR), cells/µL | 373 (275, 477) | 364 (252, 464) | .36     |
| CD4 categories at study enrollment, N (%), cells/mm³|              |                |         |
| <100                                                | 0 (0)        | 3 (4%)         | .32     |
| 100–349                                             | 26 (38)      | 36 (44)        |         |
| 350–499                                             | 26 (38)      | 36 (32)        |         |
| ≥500                                                | 16 (23)      | 16 (19)        |         |
| Unknown                                             | 1 (1)        | 1 (1)          |         |
| Prevention of mother-to-child transmission of human immunodeficiency virus regimen at delivery, N (%)|       |                |         |
| Zidovudine monotherapy + single-dose nevirapine     | 22 (32)      | 18 (22)        | .45     |
| Efavirenz + NRTI backbone                           | 39 (56)      | 52 (63)        |         |
| Lopinavir/Ritonavir + NRTI backbone                 | 2 (3)        | 3 (4)          |         |
| Nevirapine + NRTI backbone                          | 4 (6)        | 8 (10)         |         |
| None                                                | 1 (2)        | 0 (0)          |         |
| Unknown                                             | 1 (2)        | 1 (1)          |         |

Abbreviations: HIV, human immunodeficiency virus; IPT, isoniazid preventive therapy; IQR, interquartile range; NRTI, nonnucleoside transcriptase inhibitor; SD, standard deviation; TB, tuberculosis.
There was no statistically significant difference in the proportion of IPT-exposed (10%) and IPT-unexposed (17%) women who had at least 1 previous episode of TB ($P = .25$).

**IPT Exposure**

Participants reported initiating IPT at a mean gestational age of 25 weeks (SD, 6.9; Table 1), with nearly half initiating IPT in the second (48%) vs third (49%) trimesters. No participants reported taking IPT at the estimated date of conception. Almost half of IPT initiations (48%) occurred at public sector clinics prior to study enrollment, 43% occurred at screening for study enrollment, and 9% occurred more than 1 month after study enrollment. The median reported duration of IPT during pregnancy was 2 months (IQR, 1 to 4). IPT was discontinued at a median of 5 days prior to delivery (IQR, −44 to 43).

**Pregnancy, Maternal, and Infant Outcomes by IPT Exposure**

Of 69 pregnancies among IPT-exposed women, there was 1 stillbirth and 68 live births (Table 2). Of 82 pregnancies among IPT-unexposed women, there was 1 stillbirth and 1 set of twins, resulting in 82 live births. The median gestational age at birth was 39 weeks in both IPT-exposed (IQR, 38 to 40) and IPT-unexposed (IQR, 37 to 40) infants. There were 7 (10%) preterm deliveries among IPT-exposed pregnancies and 18 (22%) preterm deliveries among IPT-unexposed pregnancies ($P = .06$). There was no statistically significant difference in the proportion of infants with low birth weight (9% vs 12%; $P = .60$) or being small for gestational age (12% vs 17%; $P = .49$) between IPT-exposed and IPT-unexposed groups, respectively. There were 3 congenital anomalies including 2 infants with extra digits and 1 infant with amelia of the right arm, representing 2% of live births in both groups ($P = 1.0$). No infants were diagnosed with TB in either group, and there was 1 infant death during the neonatal period in the IPT-exposed group. There were 2 maternal deaths during the year of follow-up including 1 death at less than 42 days and 1 death at 10 months, both in the IPT-unexposed group. One IPT-unexposed mother developed TB in the first year postdelivery.

Similar proportions of mothers were hospitalized during pregnancy, at delivery, and in the postpartum period in the IPT-exposed and IPT-unexposed groups. Medical record review did not suggest IPT discontinuations or hospitalizations were due to adverse events including isoniazid-associated hepatotoxicity.

There were half as many adverse pregnancy outcomes among IPT-exposed maternal–infant pairs ($n = 11$, 16%) than among IPT-unexposed maternal–infant pairs ($n = 23$, 28%; $P = .08$; Figure 2). Similar proportions of mother–infant pairs had severe adverse pregnancy outcomes in the IPT-exposed ($n = 4$, 6%) and IPT-unexposed ($n = 4$, 5%) groups ($P = 1.0$). There was no difference in maternal, fetal, or infant death or TB disease between those IPT-exposed and IPT-unexposed maternal–infant pairs (3% vs 4%; $P = 1.0$; Table 2).

In adjusted logistic regression analysis, IPT-unexposed women had 2.5 (95% confidence interval [CI], 1.0 to 6.5; $P = .048$) times the odds of having an adverse pregnancy outcome compared with IPT-exposed women (Table 3) after controlling for CD4 count, PMTCT regimen, viral load, maternal age, BMI, and anemia. This association did not significantly change in models with continuous vs categorical predictors (data not shown). In this model, women with advanced maternal age (≥235 years) have an adjusted odds ratio of having an adverse pregnancy outcome that is 0.6 (95% CI, .1 to 2.4; $P = .50$) times that of women aged <235 years, after controlling for IPT use, CD4 count, PMTCT regimen, viral load, BMI, and anemia. When age is modeled continuously, there is no difference in the adjusted odds of having an adverse pregnancy outcome among IPT-exposed and IPT-unexposed groups. Medical record review did not suggest IPT discontinuations or hospitalizations were due to adverse events including isoniazid-associated hepatotoxicity.

| Table 2. Pregnancy, Maternal, and Infant Outcomes by Isoniazid Exposure |
|-------------------------------------------------|
| All Gestations | IPT | No IPT | P-value |
|----------------|-----|-------|---------|
| Fetal demise, a N (%) | 1 (1) | 1 (1) | 1.00 |
| Live births only | N = 68 | N = 82 | | |
| Median gestational age at birth (interquartile range), wk | 39 (38,40) | 39 (37,40) | .82 |
| Preterm, N (%), wk | 7 (10) | 18 (22) | .06 |
| 34–36 | 5 | 17 |
| 28–33 | 2 | 1 | .18 |
| <28 | 0 | 0 |
| Low birth weight (<2.5 kg), N (%) | 6 (9) | 10 (12) | .60 |
| Very low birth weight (<1.5 kg), N (%) | 2 (3) | 0 (0) | .20 |
| Small for gestational age (<10th %), N (%) | 8 (12) | 14 (17) | .49 |
| Congenital anomaly, N (%) | 1 (2) | 2 (2) | 1.00 |
| Infant deaths, N (%) | 1b (2) | 0 (0) | .45 |
| Infant TB disease, N (%) | 0 (0) | 0 (0) | |
| Maternal mortality (<42 Days), N(%) | 0 (0) | 1 (1) | 1.00 |
| Maternal TB disease, N(%) | 0 (0) | 1 (1) | 1.0 |
| Maternal hospitalization, N(%) | | | |
| During pregnancy | 9 (13) | 11 (13) | .99 |
| At delivery | 0 (0) | 2 (2.4) | .50 |
| Postpartum | 1 (1.5) | 2 (2.4) | 1.00 |
| Composite outcomes | N = 69 | N = 83 | | |
| Adverse pregnancy outcome, b N(%) | 11 (16) | 23 (28) | .08 |
| Severe adverse pregnancy outcome, c N(%) | 4 (6) | 4 (5) | 1.00 |
| Maternal/Fetal infant death or TB, N(%) | 2 (3) | 3 (4) | 1.00 |

Abbreviations: IPT, isoniazid preventive therapy; TB, tuberculosis.
aFetal demise is spontaneous abortion and stillbirth.
bThis death occurred in the neonatal period.
cComposite outcome includes fetal demise, low birth weight (<2.5 kg), prematurity (<37 weeks), and congenital anomaly.
dComposite outcome includes fetal demise (stillborn + spontaneous abortion), very low birth weight (<1.5 kg), very preterm delivery (<33 weeks), or major congenital anomaly.
outcome (adjusted odds ratio, 0.9 to 95% CI, 0.8 to 1.0) with 1-year increments in age.

**DISCUSSION**

There were 2 principle findings in this prospective observational cohort study of pregnant women living with HIV. First, we found a protective association between IPT use and adverse pregnancy outcomes after controlling for potential demographic, clinical, and HIV-related confounding factors. Second, there were no clinically relevant episodes of maternal hepatotoxicity during pregnancy or postpartum among IPT-exposed women.

While IPT was found to have a protective association with pregnancy outcomes, the mechanism for this protection remains unclear given the lack of maternal and infant TB diagnoses or mortality among IPT-unexposed participants. Importantly, no negative association was found. These results are comparable to other observational data of TB preventive therapy in pregnant women living with HIV, including 2 substudies of clinical trials assessing either daily isoniazid or weekly isoniazid/rifapentine for TB prevention [22, 23]. Our results differ from the results from TB APPRISE, where an association between IPT use during pregnancy and adverse pregnancy outcomes was reported. In our study and in TB APPRISE, women were enrolled late during the second and third trimesters, resulting in similar durations of IPT during pregnancy. Gupta et al noted that this association may be a chance finding, given the large number of outcomes assessed, and warrants confirmation [21]. Our findings do not support their finding.

While no clinically relevant hepatotoxicity was observed, we did not routinely monitor liver enzymes, and transient elevations may not have been identified. Additionally, early discontinuation of IPT limited our assessment of postpartum hepatotoxicity.

Known clinical and demographic risk factors associated with adverse pregnancy outcomes in other observational studies and clinical trials of populations living with and without HIV were modeled here as confounding factors. Point estimates for these effects are imprecise given the limited sample size. In our model, advanced maternal age appeared protective when commonly used thresholds for age were used. When analyzed as a continuous variable, maternal age was not associated with adverse pregnancy outcomes. This may be due to the small proportion of participants who were aged ≥35 years (11%). As expected, elevated viral load was associated with adverse pregnancy outcomes, but low CD4 count was not. This was a relatively healthy cohort, with few participants presenting with advanced HIV disease or severe immunosuppression. Protease inhibitors have been associated with adverse pregnancy outcomes [29, 39]. Only 5 women in this analysis had a cART regimen that contained a protease inhibitor during pregnancy; 2 (40%) had premature infants. Given

Figure 2. Pregnancy outcomes by isoniazid exposure. Composite and individual adverse pregnancy outcomes by isoniazid preventive therapy exposure. Adverse pregnancy outcome was a composite of fetal demise (spontaneous abortion and stillbirth), low birth weight (<2.5 kg), preterm delivery (<37 weeks), and major congenital anomaly. Severe adverse pregnancy outcome was a composite of fetal demise, very low birth weight (<1.5 kg), very preterm delivery (<32 weeks), and major congenital anomaly. Abbreviation: IPT, isoniazid preventive therapy.
our small sample size, we were unable to analyze specific cART regimens in the logistic regression analysis. Whether mediated through HIV disease or other factors, low BMI and anemia have also been associated with adverse pregnancy outcomes in pregnant women living with HIV [34], as seen here.

This study has several limitations. First, this was an observational study and, though we found few significant differences between groups on measured baseline factors and controlled for several potential demographic, clinical, and HIV-related confounding factors in our analysis, we cannot exclude the possibility of selection bias. It is possible that healthier women were initiated on IPT, thereby overestimating its effect on pregnancy outcomes. Second, given our limited sample size, we were unable to control for all relevant factors associated with adverse pregnancy outcomes including the specific cART regimen, timing of cART initiation with respect to conception, prior prematurity, obstetrical risk factors, and drug use including tobacco and alcohol. Third, while IPT duration was short, most women reported continuing IPT through delivery, allowing for an accurate estimation of IPT’s effect on birth outcomes. These outcomes were measured in >97% of all participants, leading to confidence in the results. Finally, our generalizability may be limited as our study was partially conducted during implementation of PMTCT option A.

In conclusion, we did not find a negative association between IPT during pregnancy and pregnancy outcomes, after controlling for CD4 count, viral load, PMTCT regimen, maternal age, BMI, and anemia. These results may provide some reassurance that IPT can be safely used in the second or third trimester of pregnancy in high-burden settings. Given the high risk of TB disease in pregnant women living with HIV and the resulting poor maternal and infant outcomes, we need additional research to confirm the safety of isoniazid during pregnancy both alone and in combination with rifapentine in new short-course TB preventive therapy regimens.

Notes

Financial support. This work was supported by the National Institutes of Child Health and Human Development (grant R01HD064354 to R. E. C.) and the National Institutes of Health (P30A1094189, 4KL2TR001077-04, and K23HD096973).

Potential conflicts of interest. R. E. C. reports that his spouse is a shareholder in Merck, and he reports consulting fees from Otsuka and Sanofi outside the submitted work. N. M. reports grants to his institution from Roche, Becton-Dickinson, and Pfizer outside the submitted work. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. World Health Organization. Global Tuberculosis r2018. Geneva, Switzerland: World Health Organization, 2018.
2. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med 2012; 185:779–84.
3. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545–50.

4. World Health Organization. Tuberculosis fact sheet: tuberculosis in women. Available at: http://www.who.int/tb/publications/tb_women_factsheet_251013.pdf?ua=1. Accessed 6 November 2019.

5. Salazar-Austin N, Hoffmann J, Cohn S, et al. Poor obstetric and infant outcomes in HIV-infected pregnant women with tuberculosis in South Africa: the Tshepiso Study. Clin Infect Dis 2018; 66:921–9.

6. Pillay T, Sturm AW, Khan M, et al. Vertical transmission of Mycobacterium tuberculosis in KwaZulu Natal: impact of HIV-1 co-infection. Int J Tuberc Lung Dis 2004; 8:59–69.

7. Tripathy SN, Tripathy SN. Tuberculosis and pregnancy. Int J Gynaecol Obstet 2003; 80:247–53.

8. Figueroa-Damiani R, Arredondo-García JL. Neonatal outcome of children born to women with tuberculosis. Arch Med Res 2001; 32:66–9.

9. Jana N, Vasishta K, Jindal SK, Khunnu B, Ghosh K. Perinatal outcome in pregnancies complicated by pulmonary tuberculosis. Int J Gynaecol Obstet 1994; 44:119–24.

10. Ratner B, Rostler AS, Salgado PS. Care, feeding and fate of premature and full term infants born of tuberculous mothers. AMA Am J Dis Child 1951; 81:471–82.

11. Schaefer G, Zervoudakis IA, Fuchs FF, David S. Pregnancy and pulmonary tuberculosis. Obstet Gynecol 1975; 46:706–15.

12. Khan M, Pillay T, Moodley J, Connolly C. Maternal mortality associated with tuberculosis-HIV coinfection in Durban, South Africa. Ann N Y Acad Sci 2000; 918:367–9.

13. Chopra S, Swatch S, Aggarwal N, Sikka P, Suri V. Pregnancy outcomes in women with tuberculosis: a 10-year experience from an Indian tertiary care hospital. Trop Doct 2017; 47:104–9.

14. Lin HC, Lin HC, Chen SF. Increased risk of low birthweight and small for gestational age infants among women with tuberculosis. BJOG 2015; 122:1598–608.

15. Grange J, Adhikari M, Ahmed Y, et al. Tuberculosis in association with HIV/AIDS emerges as a major nonobstetric cause of maternal mortality in Sub-Saharan Africa. Int J Gynaecol Obstet 2010; 108:181–3.

16. Temprano ANRS Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373:808–22.

17. Badje A, Moh R, Gabillard D, et al; Temprano ANRS 12136 Study Group. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health 2017; 5:e1080–9.

18. Moulding TS, Redeker AG, Kanel GC. Twenty isoniazid-associated deaths in one state. Am Rev Respir Dis 1989; 139:700–5.

19. Franks AL, Binkin NJ, Snider DE Jr, Rokaw WM, Becker S. Isoniazid hepatitis: a 20-year follow-up of the Texas study. Chest 1989; 96:724–9.

20. WHO/IUATLD. Tuberculosis preventive therapy in HIV-infected individuals. A joint statement of the WHO Tuberculosis Programme and the Global Programme on AIDS, and the International Union Against Tuberculosis and Lung Disease (IUATLD). Wkly Epidemiol Rec 1993; 68:361–4.

21. Gupta A, Montepiedra G, Aaron L, et al; IMPAACT P1078 TB APPRISE Study Team. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med 2019; 381:1333–46.

22. Taylor JW, Mosimanekotile B, Mathebula U, et al. Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy. Infect Dis Obstet Gynecol 2013; 2013:195637.

23. Moro RN, Scott NA, Vernon A, et al. Exposure to latent tuberculosis treatment during pregnancy. The PREVENT TB and the iAdhere trials. Ann Am Thorac Soc 2018; 15:570–80.

24. National Department of Health SA. The South African antiretroviral treatment guidelines: clinical guidelines. PMTCT (Prevention of Mother-to-Child Transmission. Available at: http://apps.who.int/medicinedocs/documents/s19153en/s19153en.pdf. Accessed 7 August 2017.

25. National Department of Health SA. The South African antiretroviral treatment guidelines. Available at: http://www.sahivsoc.org/Files/2013%20ART%20Treatment%20Guidelines%20Final%20%25March%202013%20corrected.pdf. Accessed 7 August 2017.

26. Department of Health Republic of South Africa. Guidelines for tuberculosis preventive therapy among HIV infected individuals in South Africa. Available at: https://www.who.int/hiv/pub/guidelines/south_africa_hiv_tb.pdf. Accessed 14 May 2019.

27. Villar J, Guiñan F, Fenton TR, Ohuma EO, Ismail LG, Kennedy SH; INTERGROWTH-21st Consortium. INTERGROWTH-21st very preterm size at birth reference charts. Lancet 2016; 387:844–5.

28. Centers for Disease Control and Prevention. Metropolitan Atlanta Congenital Defects Program procedures manual. Atlanta, Georgia: CDC, 1989.

29. Fowler MG, Qin M, Fiscus SA, et al; IMPAACT 1077BF/1077FF PROMISE Study Team. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med 2016; 375:1726–37.

30. Sebikari D, Farhad M, Fenton T, et al. Risk factors for adverse birth outcomes in the PROMISE 1077BF/1077FF Trial. J Acquir Immune Defic Syndr 2019; 81:521–32.

31. Cates JE, Westreich D, Edmonds A, et al. The effects of viral load burden of perinatal HIV. Infect Dis Obstet Gynecol 2015; 2015;36257.

32. World Health Organization and the Joint United Nations Programme on HIV/AIDS (UNAIDS). HIV in pregnancy: a review. Geneva, Switzerland: World Health Organization, 1998.

33. Slyker JA, Patterson J, Ambler G, et al. Correlates and outcomes of preterm birth, low birth weight, and small for gestational age in HIV-exposed uninfected infants. BMC Pregnancy Childbirth 2014; 14:7.

34. Mehta S, Manji KP, Young AM, et al. Nutritional indicators of adverse pregnancy outcomes and mother-to-child transmission of HIV among HIV-infected women. Am J Clin Nutr 2008; 87:1639–49.

35. Young S, Murray K, Mwesigwa J, et al. Maternal nutritional status predicts adverse birth outcomes among HIV-infected rural Ugandan women receiving combination antiretroviral therapy. PLoS One 2012; 7:e1934.

36. Lean SC, Derrett H, Jones RL, Heazzell AEP. Advanced maternal age and adverse pregnancy outcomes: a systematic review and meta-analysis. PLoS One 2017; 12:e0186287.

37. Larbi RK, Buchmann EJ, Matshidze PR. Pregnancy outcomes in urban black South African women aged 35 years and older. J Obstet Gynaecol 2000; 20:529–62.

38. SAS Institute Inc. Base SAS 9.3 procedures guide care N USA: SAS Institute Inc, 2011.

39. Zash R, Jacobson DL, Diseko M, et al. Comparative safety of antiretroviral treatment regimens in pregnancy. JAMA Pediatr 2017; 171:e172222.